We spoke to Professor Freek Verheugt (The Heart-Lung Centre, University Medical Centre, Nijmegen and Department of Cardiology, Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands) at C3 2019 about the findings from the recently released ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-2 (STOPDAPT-2) and the Comparison Between P2Y12 Antagonist Monotherapy and Dual Antiplatelet Therapy After DES (SMART-CHOICE) studies, and how they might impact routine practice.
Speaker’s Disclosures: Freek Verheugt is an advisor to AstraZeneca.
1. How do you interpret the findings from the recently released Short and Optimal Duration of Dual Antiplatelet Therapy-2 Study (STOPDAPT-2), and how do you think they may be incorporated into routine practice? (0:04)
2. What were your impressions of the findings of the Comparison Between P2Y12 Antagonist Monotherapy and Dual Antiplatelet Therapy After DES (SMART-CHOICE) study, and what impact do you think they might have in practice? (3:05)
touchCARDIO.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.
Filmed in partnership with C3 at the 2019 annual meeting in Orlando, Florida, June 2019.
Share this Video
Related Videos In Interventional Cardiology
David Keane, AF Symposium 2021: Challenges in Catheter Ablation
We spoke to Professor David Keane (St Vincent’s University Hospital, Dublin, Ireland) about the current challenges procedural duration and overall success in catheter ablation, and the most exciting innovations to aim to overcome these. Questions: What are the current challenges in catheter ablation in terms of procedural duration and overall success? (0.13) What are the […]
David Keane, AF Symposium 2021: Atrial Fibrillation in Patients with Hypertrophic Cardiomyopathy
We spoke to Professor David Keane (St Vincent’s University Hospital, Dublin, Ireland) about atrial fibrillation in patients with hypertrophic cardiomyopathy. Questions: What is the incidence of atrial fibrillation (AF) in people with hypertrophic cardiomyopathy (HCM)? (0.13) What is known about the efficacy and safety of catheter ablation of AF in patients with HCM compared to […]
Andrea Natale, AF Symposium 2021: Impact of Catheter Ablation on Quality of Life and Health Care Utilization
We spoke to Dr Andrea Natale (Texas Cardiac Arrhythmia Institute, Austin, TX, USA) about the most exciting recent innovations in catheter ablation technology. Questions: What is the impact of atrial fibrillation (AF) ablation on healthcare utilization and quality of life? (0.13) How should these data influence the timing of ablation strategies? (2.40) Speaker disclosures: Dr […]
Journal articles and more to your inbox
Get the latest clinical insights from touchCARDIOSign me up!